Product Information
LEVOCETIRIZINE 5 MG TABLET is a generic product labeled by Macleods Pharmaceuticals Limited, priced at $0.0511 per EA under NDC 33342020010. Its NADAC has been published 504 times since Feb 8, 2017.
FDA first approved this application on Jan 11, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Macleods Pharmaceuticals LimitedNDC
33342020010
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LEVOCETIRIZINE DIHYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA205564FDA Approved
1/11/2016
TE Code
AB
On Market Since
1/11/2016
Pharmacological Classes
Price Statistics
The NADAC for LEVOCETIRIZINE 5 MG TABLET has been published 504 times since Feb 8, 2017, and over the history we have for it it has declined 62.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0511 per EA |
|---|---|
| All-time high | $0.2097 (May 16, 2018) |
| All-time low | $0.0511 (Sep 23, 2026) |
| 52-week high | $0.0568 |
| 52-week low | $0.0511 |
| Median price | $0.0765 |
| Average price | $0.0835 |
| Largest weekly change | +51.3% (Apr 18, 2018) |
| Weeks tracked | 504 |
| Tracking since | Feb 8, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the LEVOCETIRIZINE DIHYDROCHLORIDE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Macleods Pharmaceuticals Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
LEVOCETIRIZINE DIHYDROCHLORIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LEVOCETIRIZINE 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LEVOCETIRIZINE 5 MG TABLET, manufactured by Macleods Pharmaceuticals Limited, is $0.0511 per EA (NDC 33342020010), effective Sep 30, 2026.
How has the price of LEVOCETIRIZINE 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for LEVOCETIRIZINE 5 MG TABLET has declined 62.4%. It has been tracked across 504 weekly CMS publications since Feb 8, 2017.
What are the highest and lowest recorded NADAC prices for LEVOCETIRIZINE 5 MG TABLET?
Since Feb 8, 2017, the NADAC for LEVOCETIRIZINE 5 MG TABLET has ranged from a low of $0.0511 (Sep 23, 2026) to a high of $0.2097 (May 16, 2018), with a median of $0.0765 per EA.
Are there cheaper alternatives to LEVOCETIRIZINE 5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of LEVOCETIRIZINE 5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LEVOCETIRIZINE 5 MG TABLET?
LEVOCETIRIZINE 5 MG TABLET (NDC 33342020010) is labeled by Macleods Pharmaceuticals Limited, and CMS classifies it as a generic product.